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Aminoacyl-tRNA synthetases (ARSs) are intriguing enzymes. 
Intracellularly, they catalyze the covalent attachment of amino 
acids to tRNAs and are key regulators of protein translation. 
However, these housekeeping enzymes have many other tricks 
up their sleeves. In the cell, several ARSs are also able to regu-
late gene expression at the level of transcription, splicing, and 
translation but via noncatalytic and unique mechanisms. ARSs 
also have different functions in the extracellular space, where 
they can elicit cytokine signaling responses that control angio-
genesis, induce immune and proinflammatory gene expression 
programs, and trigger cell migration or apoptosis. The response 
elicited by particular ARSs is specific to the target cells (Son et 
al., 2014). For instance, when present in the extracellular me-
dium, lysyl-tRNA synthetase (KRS) binds to macrophages and 
monocytes and activates MAPK signaling pathways that induce 
macrophage migration and TNF production (Park et al., 2005). 
How ARSs are released to the extracellular medium to carry out 
these activities is unknown. ARSs do not contain a signal pep-
tide, and pharmacological agents blocking secretion through the 
secretory pathway have no effect on the amount of ARS in the 
medium. For a while, the presence of ARSs in the extracellular 
medium was thus thought to be caused by their passive release 
from cells that have undergone necrosis. In this issue, Kim et 
al. reinvestigate how KRS is released from cancer cells and find 
that this occurs through a caspase-8– and syntenin-dependent 
incorporation of KRS in exosomes.
Proteins that include a signal peptide are secreted through 
the conventional secretory pathway to the extracellular medium, 
but leaderless proteins (i.e., proteins without a signal peptide) 
are also found in the medium. It is now clear that these lead-
erless proteins can be unconventionally delivered via at least 
three distinct mechanisms that do not involve cell lysis. The first 
mechanism is translocation across the plasma membrane (the 
so-called type I unconventional protein secretion [UPS]) either 
through self-pores and auto-transportation (as seen with FGF2 
and HIV-TAT [trans-activator of transcription]) or by the use of 
a transporter whose nature, in most cases, remains to be defined. 
The second mechanism is the type III UPS in which the lumen 
of a membranous intermediate (be it an autophagosome, a late 
endosome, or the compartment for unconventional protein se-
cretion [CUPS]) becomes enriched in leaderless cargo. These 
compartments then fuse with the plasma membrane to release 
their contents to the extracellular medium. Note that in both 
of these types of unconventional secretion, the released cargo 
is not meant to be membrane encapsulated (Rabouille, 2017). 
Third, leaderless proteins can also be released in the medium 
via extracellular vesicles that have many origins, such as plasma 
membrane blebs, apoptotic bodies, and exosomes.
Exosomes were discovered in the mid-1990s when the re-
lease of intralumenal vesicles from multivesicular bodies in B 
lymphocytes was observed (Colombo et al., 2014). Exosomes 
have been shown to be released from many cell types in vitro 
and vivo, and they mediate the spreading of different types of 
molecules from cells to cells (Colombo et al., 2014). Exosome 
formation starts with the invagination of the limiting membrane 
of an endosome in a manner that is dependent on the multim-
eric endosomal sorting complexes required for transport (ESC 
RT) complex (Babst, 2011) and ALIX (Bissig and Gruenberg, 
2014). The syntenin–syndecan complex that is present at the 
surface of endosomes also appears to play an important role in 
exosome formation (Baietti et al., 2012). Exosomes are charac-
terized by their homogenous size (∼100 nm), their cup shape, 
and their purification characteristics on flotation gradients. 
They contain membrane proteins as well as cytosolic leader-
less proteins and RNAs that are incorporated during the process 
of vesicle formation. Whether the cargo is specifically incor-
porated and concentrated in internal vesicles and how this is 
controlled remains to be investigated in most cases. Endosomes 
containing these internal vesicles, the so-called multivesicular 
bodies, fuse with the plasma membrane and release the vesicles 
into the extracellular medium as exosomes (Fig.  1; Colombo 
et al., 2014). To distinguish this third mechanism of unconven-
tional secretion that yields cargo encapsulated in a membrane 
from the other two aforementioned mechanisms, I will call it 
“exosome release” and not secretion.
KRS can bind to syntenin, a key factor for the formation 
of exosomes. This led Kim et al. (2017) to investigate whether 
the exosome release pathway accounts for the presence of KRS 
in the medium. First, they found that KRS and syntenin are re-
covered in the same flotation gradient fraction that is consis-
tent with localization in exosomes. Second, KRS release was 
strongly inhibited upon Rab35 and Rab27 depletion, two Rabs 
involved in the process of exosome formation and release (Hsu 
Cancer cells often trigger an inflammatory process, which 
in some cases may be driven by the presence of lysyl-
tRNA synthetase (KRS) in the medium. Kim et al. (2017. 
J.  Cell Biol. https ://doi .org /10 .1083 /jcb .201605118) 
now demonstrate that cleavage of the KRS by caspase-8 
inside cells triggers its interaction with syntenin and its 
release in inflammatory exosomes.
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et al., 2010; Ostrowski et al., 2010). Third, depletion of several 
ESC RT components also led to a strong reduction in KRS re-
lease. Fourth, immuno-EM revealed that KRS is localized in 
the lumen of small cup-shaped vesicles of 100 nm. Collectively, 
these four lines of evidence are consistent with the release of 
KRS in exosomes (Fig. 1). Interestingly, the presence of KRS 
in the extracellular medium appears to be entirely accounted for 
by its incorporation in exosomes, suggesting that this is the sole 
mechanism for KRS release.
KRS release in exosomes depends on its binding to syn-
tenin that guides it to ALIX. Accordingly, syntenin depletion 
inhibits KRS release. Kim et al. (2017) show that KRS binds 
syntenin via its extreme C-terminal PDZ domain (i.e., the 
last five residues of KRS), and KRS lacking this PDZ do-
main is not released. Furthermore, replacing the amino acid 
sequence of canonical KRS PDZ domain with alanines also 
prevents KRS release. This suggests that syntenin acts as a re-
ceptor for the incorporation of KRS in exosomes through the 
binding of its PDZ domain.
What regulates the specific binding of KRS to syntenin? 
One clue to this question came from the observation that the 
form of KRS present in the medium has a slightly faster mo-
bility than intracellular KRS, which is suggestive of a cleavage 
event. Both the cleavage and release of KRS in exosomes re-
quire the N terminus of KRS to be free (not tagged). Using a 
series of N-terminal truncations, the cleavage site was mapped 
between residues 12 and 13 (Fig. 1). Interestingly, the amino 
acid sequence around position 12 (VxxD) is consistent with a 
caspase cleavage site, and the substitution of aspartate 12 with 
alanine completely abrogated KRS cleavage and its release in 
exosomes. Pharmacological inhibition of caspase activity con-
firmed the role of caspases in KRS release, and RNAi screen-
ing of specific caspases revealed a key role for caspase-8 in 
this process. Depletion of caspase-8 led to a drastic reduction 
Figure 1. Model of KRS exosome release to the extracellular medium. KRS (dark blue circle) is normally found in an intracellular multimeric tRNA synthe-
tase complex, where it performs its housekeeping function of binding lysine to tRNA. The C terminus PDZ (violet box) is probably buried and does not bind 
syntenin (green bar). (1) Upon activation (caused by inflammation or/and starvation), caspase-8 cleaves the first 12 amino acids at the N terminus (orange 
box) of KRS. The PDZ domain of cleaved KRS (light blue octagon) can bind to syntenin that is localized to the endosomal membrane. (2) Syntenin mediates 
the incorporation of cleaved KRS in internal vesicles. (3) Multivesicular bodies (MVBs) fuse to the plasma membrane (PM). (4) KRS-positive inflammatory 
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of KRS release, and conversely, caspase-8 overexpression led 
to an increase. Interestingly, the release of KRS in exosomes 
was strongly stimulated by starvation, and this treatment also 
increased caspase-8 activity, whereas the activity of other 
caspases was not affected. Strikingly, Kim et al. (2017) found 
that the cleavage of the N terminus of KRS by caspase-8 modu-
lates the binding of the C terminus PDZ domain of KRS to syn-
tenin. This suggests that KRS cleavage leads to a major change 
in its conformation, which may expose the PDZ domain. Ac-
cordingly, syntenin binding to KRS is concomitant with the dis-
sociation of KRS from the multi-tRNA synthetase complex to 
which it usually belongs inside cells. Therefore, it appears that 
caspase-8–mediated cleavage leads to a change in the conforma-
tion of KRS, allowing it to bind syntenin and be released from 
the complex. This ensures the specific incorporation of cleaved 
KRS into internal vesicles and its release in exosomes (Fig. 1).
KRS is known to bind to macrophages and monocytes 
and induce them to start producing TNF, a key step in inflam-
mation and macrophage migration (Park et al., 2005). Kim et 
al. (2017) then addressed whether the KRS-containing exo-
somes are inflammatory when presented to macrophages both 
in vitro and in vivo when injected in mice. Indeed, they found 
that not only TNF but also CRG-2, IL6, and MMP9 were re-
leased by macrophages, and these become migratory when 
treated with KRS-containing exosomes. Importantly, this re-
sponse is very similar to that elicited by naked KRS. This sug-
gests that KRS release in exosomes triggers inflammation and 
may help create a microenvironment for cancer cell survival 
and potentiate metastasis.
However, many questions about the process of KRS re-
lease remain to be answered. First, as mentioned above, star-
vation stimulates exosome production and the incorporation of 
KRS therein. Although the mechanism of this stimulation is not 
well understood, it is interesting that exosome release is stim-
ulated by stress, as this is also observed for many other UPS 
pathways (Rabouille, 2017). Second, syntenin is proposed to 
be the KRS receptor mediating its incorporation into internal 
vesicles of endosomes. Syntenin itself is recruited to the en-
dosomal membrane through its binding to the proteoglycan 
syndecan (Baietti et al., 2012). It will therefore be interesting 
to show whether KRS release in exosomes is also dependent 
on syndecan. Third, KRS in exosomes is as potent as naked 
KRS in stimulating the inflammatory response and migration 
of macrophages. It seems likely that KRS is released from exo-
somes, but the mechanism of this release needs to be better un-
derstood. Are exosomes taken up in macrophage endosomes, 
and is the membrane dissolved there? Does KRS become mem-
brane free in the medium?
KRS is now established as a caspase-8 substrate. Caspase-8 
normally exists as a pro–caspase-8 enzyme that is cleaved and 
activated by inflammation. Of note, this caspase-8 activity does 
not appear to be triggering apoptosis. This suggests that a small 
level of inflammation around the cancer cells activates caspase-8, 
which triggers more inflammation through the release of KRS. 
This in turn activates pro-IL1β in macrophages and leads to the 
release of mature IL1β, leading to full-blown inflammation and 
potentially creating a niche for cancer cell survival and pro-
liferation. Interestingly, mature IL1β is also unconventionally 
secreted (by type I and III depending on the stress; Rabouille, 
2017), suggesting that the inflammation triggered by cancer cells 
might be the sum of several unconventional secretion modes.
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